%A Behzatoglu,Kemal %D 2021 %J Pathology and Oncology Research %C %F %G English %K Tumor biology,metastasis,breast carcinoma metastasis,Giant Cell Tumor of Bone,EMMT,osteoclast tumor biology metastasis breast carcinoma metastasis giant cell tumor of bone EM %Q %R 10.3389/pore.2021.609472 %W %L %M %P %7 %8 2021-April-30 %9 Review %+ Prof Kemal Behzatoglu,Department of Pathology, Faculty of Medicine, Acıbadem University,Istanbul,Türkiye,kbehzatoglu@hotmail.com %# %! Osteoclast in tumor biology. %* %< %T Osteoclasts in Tumor Biology: Metastasis and Epithelial-Mesenchymal-Myeloid Transition %U https://www.por-journal.com/articles/10.3389/pore.2021.609472 %V 27 %0 JOURNAL ARTICLE %@ 1532-2807 %X Osteoclast is a specialized cell that originates from monocytic lineage, communicates closely with osteoblasts under physiological conditions, participates in bone modeling and re-modeling, contributes to calcium homeostasis and osteoimmunity. In pathological conditions, it is involved in many tumors such as giant cell bone tumor (osteoclastoma), aneurysmal bone cyst, osteosarcoma, and metastatic cancers, and it usually causes local spread and progression of the tumor, working against the host. Since osteoclasts play an active role in primary bone tumors and bone metastases, the use of anti-osteoclastic agents significantly reduces the mortality and morbidity rates of patients by preventing the progression and local spread of tumors. Osteoclasts also accompany undifferentiated carcinomas of many organs, especially pancreas, thyroid, bladder and ovary. Undifferentiated carcinomas rich in osteoclasts have osteoclastoma-like histology. In these organs, osteoclastoma-like histology may accompany epithelial carcinomas, and de novo, benign and borderline tumors. Mature and immature myeloid cells, including osteoclasts, play an active role in the tumor progression in primary and metastatic tumor microenvironment, in epithelial-mesenchymal transition (EMT), mesenchymal-epithelial-transition (MET), and cancer stem cell formation. Additionally, they are the most suitable candidates for cancer cells in cell fusion due to their evolutionary fusion capabilities. Myeloid features and markers (CD163, CD33, CD68 etc.) can be seen in metastatic cancer cells. Consequently, they provide metastatic cancer cells with motility, margination, transmigration, chemotaxis, phagocytosis, angiogenesis, matrix degradation, and resistance to chemotherapy. For these reasons, we think that the concept of Epithelial-Mesencyhmal-Myeloid-Transition (EMMT) will be more accurate than EMT for cancer cells with myeloid properties.